China Industrial-Grade Mixed Glycerin Industry Dynamics Analysis and Development Trend Forecast Report, 2025–2031

5.6.4 Vance Group Ltd.: Company Profile and Core Business 5.6.5 Vance Group Ltd.: Latest Corporate Developments 5.7 PMC Group, Inc. 5.7.1 PMC Group, Inc.: Basic Information, Industrial-Grade Mixed Glycerin Production Bases, Sales Regions, Competitors, and Market Position 5.7.2 PMC Group, Inc.: Industrial-Grade Mixed Glycerin Product Specifications, Parameters, and Market Applications 5.7.3 PMC Group, Inc.: Industrial-Grade Mixed Glycerin Sales Volume, Revenue, Pricing, and Gross Margin (2021–2025) 5.7.4 PMC Group, Inc.: Company Profile and Core Business 5.7.5 PMC Group, Inc.: Latest Corporate Developments 5.8 The Vegetable Vitamin Foods Company Pvt. Ltd. 5.8.1 The Vegetable Vitamin Foods Company Pvt. Ltd.: Basic Information, Industrial-Grade Mixed Glycerin Production Bases, Sales Regions, Competitors, and Market Position 5.8.2 The Vegetable Vitamin Foods Company Pvt. Ltd.: Industrial-Grade Mixed Glycerin Product Specifications, Parameters, and Market Applications 5.8.3 The Vegetable Vitamin Foods Company Pvt. Ltd.: Industrial-Grade Mixed Glycerin Sales Volume, Revenue, Pricing, and Gross Margin (2021–2025) 5.8.4 The Vegetable Vitamin Foods Company Pvt. Ltd.: Company Profile and Core Business 5.8.5 The Vegetable Vitamin Foods Company Pvt. Ltd.: Latest Corporate Developments 5.9 AEMETIS, INC. 5.9.1 AEMETIS, INC.: Basic Information, Industrial-Grade Mixed Glycerin Production Bases, Sales Regions, Competitors, and Market Position 5.9.2 AEMETIS, INC.: Industrial-Grade Mixed Glycerin Product Specifications, Parameters, and Market Applications 5.9.3 AEMETIS, INC.: Industrial-Grade Mixed Glycerin Sales Volume, Revenue, Pricing, and Gross Margin (2021–2025) 5.9.4 AEMETIS, INC.: Company Profile and Core Business 5.9.5 AEMETIS, INC.: Latest Corporate Developments 5.10 Bunge Argentina S.A. 5.10.1 Bunge Argentina S.A.: Basic Information, Industrial-Grade Mixed Glycerin Production Bases, Sales Regions, Competitors, and Market Position 5.10.2 Bunge Argentina S.A.: Industrial-Grade Mixed Glycerin Product Specifications, Parameters, and Market Applications

Moderna’s Surge: What Is Changfeng Pharma’s Scarce Value from the Perspective of an Inhaled Platform?

The R&D design concept of ICF001 is highly homologous to Insmed’s TPIP: it employs prodrug modification technology to enable slow release of the active pharmaceutical ingredient after pulmonary deposition—thereby lowering peak plasma drug concentrations, reducing systemic side effects, improving patients’ long-term adherence, and optimizing airway irritation to potentially lower the incidence of cough—the most prominent adverse effect associated with current inhaled pulmonary arterial hypertension (PAH) therapies. On the evening of August 24, 2026, Changfeng Pharma announced the expansion of ICF001’s indications from PAH and PH-ILD to include PAH, PH-ILD, IPF (idiopathic pulmonary fibrosis), and PPF (progressive pulmonary fibrosis)—aligning fully with Insmed’s TPIP—and positioning ICF001 as a blockbuster therapy for severe respiratory diseases. (Announcement dated August 24, 2026) Simultaneously, the company is pursuing global development and commercialization: it plans to initiate Phase I clinical trials domestically, and may subsequently pursue global multicenter development, regional licensing, co-development, or other collaborative models. Moreover, Changfeng Pharma has another inhaled dry powder formulation for pulmonary fibrosis—ICF004 (a globally first-in-class innovative drug). Its IND application received approval from China’s NMPA in June 2026, with indications covering IPF and PPF. As a global first-in-class candidate, ICF004 validates the company’s platform capabilities in high-barrier complex formulations coupled with novel drug development. Thus, ICF001 and ICF004 together advance Changfeng Pharma’s dual focus on pulmonary arterial hypertension and pulmonary fibrosis—two major severe respiratory disease areas—further amplifying the value of its inhaled delivery platform. This strategic synergy mirrors Insmed’s approach of leveraging a single pipeline asset (TPIP) across multiple indications. Globally, no inhaled formulation for PF-ILD has yet been approved. In both China and the U.S., only two oral drugs are currently available—but they commonly cause gastrointestinal intolerance, hepatotoxicity, and other systemic adverse effects; some patients discontinue treatment due to intolerability, reflecting a significant unmet clinical need. ICF004 utilizes lung-localized, targeted inhaled delivery, theoretically enhancing drug exposure at the disease site while minimizing systemic toxicity. Within China, comparable candidates are scarce, and its clinical development timeline ranks among the most advanced globally—endowing it with strong potential to become a blockbuster therapy. Returning to the implications of Moderna’s stock surge: the revaluation of innovative drugs begins with conceptual appeal but ultimately hinges on robust, real-world clinical data. Capital markets are willing to pay a premium for platforms addressing massive unmet clinical needs—provided clinical trials progressively validate their underlying hypotheses. Insmed’s rise was likewise not driven by narrative alone, but by systematically transforming ideas into clinical evidence. For Changfeng Pharma’s ICF001 and ICF004, initial regulatory approvals have already demonstrated the strength of its inhaled innovation platform; subsequent clinical readouts across development phases will serve as the core catalysts determining the company’s valuation. Having undergone industry consolidation over recent years, China’s innovative pharmaceutical sector has moved beyond the era of pure concept speculation. Companies that genuinely possess platform capabilities, target globally unmet clinical needs, and maintain a commercially viable foundation will continue attracting capital—yet such enterprises remain exceedingly rare in China.

Aemetis Stock Jumps on Operating Profit Return Amid Liquidity Concerns

Aug 10, 2026

Aemetis shares gained 5.5% following Q2 earnings showing a $5.8 million operating profit and 20% revenue increase fueled by low-carbon fuel incentives. Yet, liquidity risks and reliance on policy support persist.

Sahm

2026-03-25

Biofuels Conference Gives Aemetis CEO Lifetime Achievement Honor

2026-03-25

Aemetis CEO Eric McAfee Receives Holmberg Award for Lifetime Achievement in the Bioeconomy

2026-03-28

Aemetis Price Target Increased by 59.28% to $11.27

2026-04-14

Aemetis Price Target Increased by 59.28% to $11.27

2026-04-27

Aemetis Schedules 2026 Annual Meeting